• Explore /
  • Poster
  • / Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.

Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.

Abstract Video & Slides Poster

Authors

null

Hermann Einsele

Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany

Hermann Einsele , Samir S. Parekh , Deepu Madduri , Bianca Santomasso , Jaime Gállego Pérez De Larraya , Niels W.C.J. van de Donk , Bertrand Arnulf , Maria-Victoria Mateos , Kevin C. De Braganca , Helen Varsos , Marlene Carrasco-Alfonso , Muhammad Akram , Nikoletta Lendvai , Carolyn Chang Jackson , Yunsi Olyslager , Enrique Zudaire , Claire Li , Dong Geng , Andrzej J. Jakubowiak , Adam D. Cohen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04133636

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8028)

DOI

10.1200/JCO.2021.39.15_suppl.8028

Abstract #

8028

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Doris K. Hansen

First Author: James R. Berenson

First Author: Yi Zheng

First Author: Niels W.C.J. van de Donk